Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,accountsPayable,longTermDebt,otherCurrentAssets,treasuryStock,otherAssets,otherStockholderEquity,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,totalCashFromOperatingActivities,depreciation,changeToNetincome,changeInCash,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,shortName,esgPopulated,tradeable,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchangeDataDelayedBy,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,longName,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,country,maxAge,address1,fax,industry,address2
t0,IRBS,-13307302.0,17083000,,,-343313,,-343313,401501,0,-401501,-401501,,-481924,,,,0,0,401501,0,58188,,-343313,-227908,19713733.0,7402098.0,-13307302.0,303200.0,65796.0,17082.0,-33038117.0,895153.0,6506945.0,3613895.0,20866.0,44930.0,2303786.0,,,,,,492044.0,150000.0,150000.0,-45428.0,-150000.0,1847.0,-615309.0,,-6462015.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,IR BIOSCIENCES HOLDINGS INC,False,False,PNK,0.0001,1629123385,0.0,0.0001,0.0001,0.0001,600200,PRE,0,4,0.0,1.0E-4 - 1.0E-4,0.0001,0.0,0.0,0,0,finmb_3110710,IR Biosciences Holdings Inc.,Other OTC,USD,3401,36400,0.0,0.0,1.0E-4 - 6.0E-4,-0.0005,-0.8333333,0.0001,0.0006,-0.342,-0.779,0.00013333333,-3.3333337e-05,-0.25000003,0.00020074075,-0.00010074075,-0.50184506,1700,-0.0001283697,15,America/New_York,EDT,-14400000,545.1,,,0.0006,0.0001,0.0001,0.0002,3.4k,36.4k,17.08M,,,0.00%,0.00%,,,,,,,,,,,,,,,,"Dec 30, 2010","Dec 30, 2010",0.00%,0.00%,-791.97%,,,,,,-2.85M,-5.41M,-0.3420,,,,3.67M,,0.01,-0.78,-430.31k,891.61k,Value,85258,Services,4,"IR BioSciences Holdings, Inc. operates as a development stage biotechnology company in the United States. The company, through its subsidiary, ImmuneRegen BioSciences, Inc., engages in the research and development of therapies in the areas of pulmonary fibrosis, influenza infection, and radiation-induced Neutropenia. It is involved in the development of Homspera, and its derivates Radilex and Viprovex, for human stem cell stimulation, immune system stimulation and anti-infective activity, vaccine adjuvancy, and wound healing. IR BioSciences Holdings, Inc. was founded in 1999 and is headquartered in Scottsdale, Arizona.",Scottsdale,480-922-3926,AZ,United States,86400,8777 East Via de Ventura,480-922-4781,Research Services,Suite 280
t-1,IRBS,-13081197.0,17083000,,,-2794205,,-2789992,341402,0,-341402,-341402,,-243270,,,,-4213,0,341402,0,-2452803,,-2789992,-3034397,19596525.0,7189729.0,-13081197.0,303200.0,27532.0,17082.0,-32694804.0,1679670.0,2406324.0,,22713.0,4819.0,1933944.0,3103735.0,,,,,451949.0,150000.0,150000.0,29589.0,-150000.0,2027.0,2211335.0,,-2401505.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,IR BIOSCIENCES HOLDINGS INC,False,False,PNK,0.0001,1629123385,0.0,0.0001,0.0001,0.0001,600200,PRE,0,4,0.0,1.0E-4 - 1.0E-4,0.0001,0.0,0.0,0,0,finmb_3110710,IR Biosciences Holdings Inc.,Other OTC,USD,3401,36400,0.0,0.0,1.0E-4 - 6.0E-4,-0.0005,-0.8333333,0.0001,0.0006,-0.342,-0.779,0.00013333333,-3.3333337e-05,-0.25000003,0.00020074075,-0.00010074075,-0.50184506,1700,-0.0001283697,15,America/New_York,EDT,-14400000,545.1,,,0.0006,0.0001,0.0001,0.0002,3.4k,36.4k,17.08M,,,0.00%,0.00%,,,,,,,,,,,,,,,,"Dec 30, 2010","Dec 30, 2010",0.00%,0.00%,-791.97%,,,,,,-2.85M,-5.41M,-0.3420,,,,3.67M,,0.01,-0.78,-430.31k,891.61k,Value,85258,Services,4,"IR BioSciences Holdings, Inc. operates as a development stage biotechnology company in the United States. The company, through its subsidiary, ImmuneRegen BioSciences, Inc., engages in the research and development of therapies in the areas of pulmonary fibrosis, influenza infection, and radiation-induced Neutropenia. It is involved in the development of Homspera, and its derivates Radilex and Viprovex, for human stem cell stimulation, immune system stimulation and anti-infective activity, vaccine adjuvancy, and wound healing. IR BioSciences Holdings, Inc. was founded in 1999 and is headquartered in Scottsdale, Arizona.",Scottsdale,480-922-3926,AZ,United States,86400,8777 East Via de Ventura,480-922-4781,Research Services,Suite 280
t-2,IRBS,-10269371.0,17083000,,,1181363,,1181363,1226835,0,-1226835,-1226835,,-495159,,,,0,0,1226835,0,2408198,,1181363,1181363,19619511.0,10312680.0,-10269371.0,485068.0,43309.0,15930.0,-29904812.0,1396648.0,5164406.0,3000000.0,24740.0,18569.0,1632456.0,3751626.0,1139.0,,,,558000.0,150000.0,150000.0,42005.0,-150000.0,2099.0,-2078627.0,,-5145837.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,IR BIOSCIENCES HOLDINGS INC,False,False,PNK,0.0001,1629123385,0.0,0.0001,0.0001,0.0001,600200,PRE,0,4,0.0,1.0E-4 - 1.0E-4,0.0001,0.0,0.0,0,0,finmb_3110710,IR Biosciences Holdings Inc.,Other OTC,USD,3401,36400,0.0,0.0,1.0E-4 - 6.0E-4,-0.0005,-0.8333333,0.0001,0.0006,-0.342,-0.779,0.00013333333,-3.3333337e-05,-0.25000003,0.00020074075,-0.00010074075,-0.50184506,1700,-0.0001283697,15,America/New_York,EDT,-14400000,545.1,,,0.0006,0.0001,0.0001,0.0002,3.4k,36.4k,17.08M,,,0.00%,0.00%,,,,,,,,,,,,,,,,"Dec 30, 2010","Dec 30, 2010",0.00%,0.00%,-791.97%,,,,,,-2.85M,-5.41M,-0.3420,,,,3.67M,,0.01,-0.78,-430.31k,891.61k,Value,85258,Services,4,"IR BioSciences Holdings, Inc. operates as a development stage biotechnology company in the United States. The company, through its subsidiary, ImmuneRegen BioSciences, Inc., engages in the research and development of therapies in the areas of pulmonary fibrosis, influenza infection, and radiation-induced Neutropenia. It is involved in the development of Homspera, and its derivates Radilex and Viprovex, for human stem cell stimulation, immune system stimulation and anti-infective activity, vaccine adjuvancy, and wound healing. IR BioSciences Holdings, Inc. was founded in 1999 and is headquartered in Scottsdale, Arizona.",Scottsdale,480-922-3926,AZ,United States,86400,8777 East Via de Ventura,480-922-4781,Research Services,Suite 280
t-3,IRBS,-12081713.0,17083000,,,-3326202,,-3326202,889838,0,-889838,-889838,,-486149,,,,0,0,889838,0,-2436364,,-3326202,-3326202,18969888.0,12157742.0,-12081713.0,303200.0,76029.0,14130.0,-31086175.0,4397040.0,3413152.0,2000000.0,26839.0,41472.0,1085742.0,4347550.0,2500.0,20444.0,7718.0,20444.0,325411.0,150000.0,150000.0,29090.0,-280309.0,2358.0,2403875.0,-280309.0,-3371680.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,IR BIOSCIENCES HOLDINGS INC,False,False,PNK,0.0001,1629123385,0.0,0.0001,0.0001,0.0001,600200,PRE,0,4,0.0,1.0E-4 - 1.0E-4,0.0001,0.0,0.0,0,0,finmb_3110710,IR Biosciences Holdings Inc.,Other OTC,USD,3401,36400,0.0,0.0,1.0E-4 - 6.0E-4,-0.0005,-0.8333333,0.0001,0.0006,-0.342,-0.779,0.00013333333,-3.3333337e-05,-0.25000003,0.00020074075,-0.00010074075,-0.50184506,1700,-0.0001283697,15,America/New_York,EDT,-14400000,545.1,,,0.0006,0.0001,0.0001,0.0002,3.4k,36.4k,17.08M,,,0.00%,0.00%,,,,,,,,,,,,,,,,"Dec 30, 2010","Dec 30, 2010",0.00%,0.00%,-791.97%,,,,,,-2.85M,-5.41M,-0.3420,,,,3.67M,,0.01,-0.78,-430.31k,891.61k,Value,85258,Services,4,"IR BioSciences Holdings, Inc. operates as a development stage biotechnology company in the United States. The company, through its subsidiary, ImmuneRegen BioSciences, Inc., engages in the research and development of therapies in the areas of pulmonary fibrosis, influenza infection, and radiation-induced Neutropenia. It is involved in the development of Homspera, and its derivates Radilex and Viprovex, for human stem cell stimulation, immune system stimulation and anti-infective activity, vaccine adjuvancy, and wound healing. IR BioSciences Holdings, Inc. was founded in 1999 and is headquartered in Scottsdale, Arizona.",Scottsdale,480-922-3926,AZ,United States,86400,8777 East Via de Ventura,480-922-4781,Research Services,Suite 280
